Abstract CT153: Phase I trial of intratumoral administration of autologous <i>CCL21</i> gene-modified dendritic cells in combination with pembrolizumab for advanced NSCLC: Feasibility of repeated IT injections
Bin Liu(Central South University), Steven M. Dubinett(University of California, Los Angeles), Camelia Dumitras(University of California, Los Angeles), Robert D. Suh(University of California, Los Angeles), Anita Kaul(University of California, Los Angeles), Kanwarpal Kahlon(City Of Hope National Medical Center), Gregory A. Fishbein(University of California, Los Angeles), Raymond J. Lim(University of California, Los Angeles), Jonathan W. Goldman(University of California, Los Angeles), Michael S. Oh(Northwestern University), Ramin Salehi‐Rad(University of California, Los Angeles), Scott Oh, Linh M. Tran(University of California, Los Angeles), Scott Genshaft(University of California, Los Angeles), Edward B. Garon(University of California, Los Angeles), Kostyantyn Krysan(University of California, Los Angeles), David Elashoff(University of California, Los Angeles), Aaron Lisberg(University of California, Los Angeles), Zhe Jing(University of California, Los Angeles), Fereidoun Abtin, Shahryar A. Ashouri, Jay M. Lee(University of California, Los Angeles)
Cited by 1
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2015|664
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC
|New England Journal of Medicine|2023|605
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|459